Special Edition: Managing MS Spasticity, Issue 2

Clinical Opinions: Managing Spasticity in Individuals with MS

In this issue:

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  

These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. 

Learning objectives:

  • Describe the clinical manifestations of spasticity, its incidence in people with MS, and its impact on quality of life. 
  • Discuss current management strategies for spasticity, including efficacy and limitations.
  • Describe the evidence base supporting the use of cannabis-based therapies for MS spasticity, including efficacy, potential side effects and cautions, and available/emerging products. 

Authors:

Michael Kornberg, MD, PhD
Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Scott Newsome, DO, MSCS, FAAN, FANA
Scott Newsome, DO, MSCS, FAAN, FANA

Associate Professor of Neurology 
Johns Hopkins Hospital 
Baltimore, MD

Alexius Sandoval, MD
Alexius Sandoval, MD

Medical Director, Multiple Sclerosis Rehabilitation Program
Johns Hopkins Hospital
Baltimore, MD

Michelle H. Cameron, MD, PT, MCR
Michelle H. Cameron, MD, PT, MCR

Professor, Department of Neurology
Oregon Health & Science University
Portland, OR

Program Directors:

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: May 12, 2023
Expiration date: May 11, 2024